氨基酸代谢在肺动脉高压中的作用探讨

黄 金玲
青海大学医学院

摘要


氨基酸通过参与细胞内多种代谢途径发挥促进生物体细胞生长和增殖、调节免疫等多项功能，肺动脉高压
的发展与肺血管细胞（血管内皮细胞、成纤维细胞等）异常增生、凋亡密切相关，谷氨酰胺、精氨酸等数种非必需
氨基酸被发现参与肺动脉高压病程进展中细胞异常增殖和血管扩张，本文通过介绍氨基酸代谢在肺动脉高压发病过
程中的作用情况，为肺动脉高压治疗提供新思路。

关键词


氨基酸代谢；肺动脉高压

全文:

PDF


参考


[1]Wu G. Amino acids: metabolism, functions, and

nutrition. Amino Acids. 2009 May;37(1):1-17. doi: 10.1007/

s00726-009-0269-0. Epub 2009 Mar 20. PMID: 19301095.

[2]Kelly B, Pearce EL. Amino Assets: How Amino Acids

Support Immunity. Cell Metab. 2020 Aug 4;32(2):154-175.

doi: 10.1016/j.cmet.2020.06.010. Epub 2020 Jul 9. PMID:

32649859.

[3]Ryan JJ, Archer SL. Emerging concepts in the

molecular basis of pulmonary arterial hypertension: part

I: metabolic plasticity and mitochondrial dynamics in the

pulmonary circulation and right ventricle in pulmonary arterial

hypertension. Circulation. 2015 May 12;131(19):1691-702.

doi: 10.1161/CIRCULATIONAHA.114.006979. PMID:

25964279; PMCID: PMC4429908.

[4]Chandel NS. Amino Acid Metabolism. Cold

Spring Harb Perspect Biol. 2021 Apr 1;13(4):a040584. doi:

10.1101/cshperspect.a040584. PMID: 33795250; PMCID:

PMC8015690.

[5]Wu G. Synthesis of citrulline and arginine

from proline in enterocytes of postnatal pigs. Am J

Physiol. 1997 Jun;272(6 Pt 1):G1382-90. doi: 10.1152/

ajpgi.1997.272.6.G1382. PMID: 9227473.

[6]Zhang J, Pavlova NN, Thompson CB. Cancer cell

metabolism: the essential role of the nonessential amino acid,

glutamine. EMBO J. 2017 May 15;36(10):1302-1315. doi:

10.15252/embj.201696151. Epub 2017 Apr 18. PMID:

28420743; PMCID: PMC5430235.

[7]陈幸，邓燕.巨噬细胞的谷氨酰胺代谢重编程在

心血管疾病中的作用[J].实用医学杂志，2024，40（22）：

3262-3267.

[8]Nicklin P, Bergman P, Zhang B, Triantafellow E,

Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C,

Myer VE, MacKeigan JP, Porter JA, Wang YK, Cantley

LC, Finan PM, Murphy LO. Bidirectional transport of

amino acids regulates mTOR and autophagy. Cell. 2009 Feb

6;136(3):521-34. doi: 10.1016/j.cell.2008.11.044. PMID:

19203585; PMCID: PMC3733119.

[9]Souba WW, Herskowitz K, Plumley DA.

Lung glutamine metabolism. JPEN J Parenter Enteral

Nutr. 1990 Jul-Aug;14(4 Suppl):68S-70S. doi:

10.1177/014860719001400407. PMID: 2205734.

[10]Ge J, Cui H, Xie N, Banerjee S, Guo S, Dubey

S, Barnes S, Liu G. Glutaminolysis Promotes Collagen

Translation and Stability via α-Ketoglutarate-mediated

mTOR Activation and Proline Hydroxylation. Am J

Respir Cell Mol Biol. 2018 Mar;58(3):378-390. doi:

10.1165/rcmb.2017-0238OC. PMID: 29019707; PMCID:

PMC5854958.

[11]Xu H, Pearl RG. Effect of l-glutamine

on pulmonary hypertension in the perfused rabbit

lung. Pharmacology. 1994 Apr;48(4):260-4. doi:

10.1159/000139188. PMID: 8177911.

[12]Bertero T, Oldham WM, Cottrill KA, Pisano S,

Vanderpool RR, Yu Q, Zhao J, Tai Y, Tang Y, Zhang

YY, Rehman S, Sugahara M, Qi Z, Gorcsan J 3rd, Vargas

SO, Saggar R, Saggar R, Wallace WD, Ross DJ, Haley KJ,

Waxman AB, Parikh VN, De Marco T, Hsue PY, Morris

A, Simon MA, Norris KA, Gaggioli C, Loscalzo J, Fessel J,

Chan SY. Vascular stiffness mechanoactivates YAP/TAZdependent glutaminolysis to drive pulmonary hypertension.

J Clin Invest. 2016 Sep 1;126(9):3313-35. doi: 10.1172/

JCI86387. Epub 2016 Aug 22. PMID: 27548520; PMCID:

PMC5004943.

[13]Wu G, Morris SM Jr. Arginine metabolism: nitric

oxide and beyond. Biochem J. 1998 Nov 15;336 ( Pt 1)(Pt

1):1-17. doi: 10.1042/bj3360001. PMID: 9806879; PMCID:

PMC1219836.[14]Sasaki A, Doi S, Mizutani S, Azuma H. Roles of

accumulated endogenous nitric oxide synthase inhibitors,

enhanced arginase activity, and attenuated nitric oxide

synthase activity in endothelial cells for pulmonary

hypertension in rats. Am J Physiol Lung Cell Mol Physiol.

2007 Jun;292(6):L1480-7. doi: 10.1152/ajplung.00360.2006.

Epub 2007 Feb 23. PMID: 17322279.

[15]López V, Moraga FA, Llanos AJ, Ebensperger G,

Taborda MI, Uribe E. Plasmatic Concentrations of ADMA

and Homocystein in Llama (Lama glama) and Regulation of

Arginase Type II: An Animal Resistent to the Development

of Pulmonary Hypertension Induced by Hypoxia. Front

Physiol. 2018 May 29;9:606. doi: 10.3389/fphys.2018.00606.

PMID: 29896110; PMCID: PMC5986928.

[16]Beyer J, Kolditz M, Ewert R, Rubens C, Opitz C,

Schellong S, Hoeffken G, Halank M. L-arginine plasma levels

and severity of idiopathic pulmonary arterial hypertension.

Vasa. 2008 Feb;37(1):61-7. doi: 10.1024/0301-1526.37.1.61.

PMID: 18512543.

[17]Mitani Y, Maruyama K, Sakurai M. Prolonged

administration of L-arginine ameliorates chronic pulmonary

hypertension and pulmonary vascular remodeling in rats.

Circulation. 1997 Jul 15;96(2):689-97. PMID: 9244244.

[18]Adeva-Andany M, Souto-Adeva G, AmeneirosRodríguez E, Fernández-Fernández C, Donapetry-García

C, Domínguez-Montero A. Insulin resistance and glycine

metabolism in humans. Amino Acids. 2018 Jan;50(1):11-

27. doi: 10.1007/s00726-017-2508-0. Epub 2017 Nov 1.

PMID: 29094215.

[19]Hall JC. Glycine. JPEN J Parenter Enteral Nutr. 1998

Nov-Dec;22(6):393-8. doi: 10.1177/0148607198022006393.

PMID: 9829614.

[20]Yu Q, Tai YY, Tang Y, Zhao J, Negi V, Culley

MK, Pilli J, Sun W, Brugger K, Mayr J, Saggar R, Saggar R,

Wallace WD, Ross DJ, Waxman AB, Wendell SG, Mullett

SJ, Sembrat J, Rojas M, Khan OF, Dahlman JE, Sugahara

M, Kagiyama N, Satoh T, Zhang M, Feng N, Gorcsan J 3rd,

Vargas SO, Haley KJ, Kumar R, Graham BB, Langer R,

Anderson DG, Wang B, Shiva S, Bertero T, Chan SY. BOLA

(BolA Family Member 3) Deficiency Controls Endothelial

Metabolism and Glycine Homeostasis in Pulmonary

Hypertension. Circulation. 2019 May 7;139(19):2238-2255.

doi: 10.1161/CIRCULATIONAHA.118.035889. PMID:

30759996; PMCID: PMC6519484.

[21]Guignabert C, Dorfmüller P. Pathology and

Pathobiology of Pulmonary Hypertension. Semin Respir Crit

Care Med. 2017 Oct;38(5):571-584. doi: 10.1055/s-0037-

1606214. Epub 2017 Oct 15. PMID: 29032561.

[22]Hatano S, Strasser T, eds. Primary Pulmonary

Hypertension. Report on a WHO Meeting. Geneva, World

Health Organization, 1975

[23]Humbert M, Kovacs G, Hoeper MM, Badagliacca

R, Berger RMF, Brida M, Carlsen J, Coats AJS, EscribanoSubias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas

G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM,

Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon

O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A,

Delcroix M, Rosenkranz S; ESC/ERS Scientific Document

Group. 2022 ESC/ERS Guidelines for the diagnosis and

treatment of pulmonary hypertension. Eur Heart J. 2022

Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237.

Erratum in: Eur Heart J. 2023 Feb 23;: PMID: 36017548.

[24]Simonneau G, Montani D, Celermajer DS, Denton

CP, Gatzoulis MA, Krowka M, et al. Haemodynamic

Definitions and Updated Clinical Classification of Pulmonary

Hypertension. Eur Respir J. 2019;53(1):1801913. doi:

10.1183/13993003.01913-2018.

[25]Rose-Jones LJ, Mclaughlin VV. Pulmonary

hypertension: types and treatments. Curr Cardiol Rev.

2015;11(1):73-9. doi: 10.2174/1573403x0966613111716412

2. PMID: 24251459; PMCID: PMC4347212.

[26]Macera F, Vachiéry JL. Management of Pulmonary

Hypertension in Left Heart Disease. Methodist Debakey

Cardiovasc J. 2021 Jul 1;17(2):115-123. doi: 10.14797/

RKQN5397. PMID: 34326931; PMCID: PMC8298119.

[27]于雪琪，蔡成森，彭召云，等.慢性阻塞性肺疾

病并肺心病急性加重期肺动脉高压的机制研究进展[J].临

床肺科杂志，2025，30（01）：131-137.

[28]Papamatheakis DG, Poch DS, Fernandes TM,

Kerr KM, Kim NH, Fedullo PF. Chronic Thromboembolic

Pulmonary Hypertension: JACC Focus Seminar. J Am Coll

Cardiol. 2020 Nov 3;76(18):2155-2169. doi: 10.1016/j.jacc.2020.08.074. PMID: 33121723.

[29]Robbins IM, Pugh ME, Hemnes AR. Update on

chronic thromboembolic pulmonary hypertension. Trends

Cardiovasc Med. 2017 Jan;27(1):29-37. doi: 10.1016/

j.tcm.2016.05.010. Epub 2016 May 25. PMID: 27345156.

[30]Hambly N, Alawfi F, Mehta S. Pulmonary

hypertension: diagnostic approach and optimal management.

CMAJ. 2016 Aug 9;188(11):804-812. doi: 10.1503/

cmaj.151075. Epub 2016 May 2. PMID: 27141034; PMCID:

PMC4978577.

[31]Thenappan T, Ormiston ML, Ryan JJ, Archer SL.

Pulmonary arterial hypertension: pathogenesis and clinical

management. BMJ. 2018 Mar 14;360:j5492. doi: 10.1136/

bmj.j5492. PMID: 29540357; PMCID: PMC6889979.

[32]Patel R, Aronow WS, Patel L, Gandhi K, Desai H,

Kaul D, Sahgal SP. Treatment of pulmonary hypertension.

Med Sci Monit. 2012 Apr;18(4):RA31-9. doi: 10.12659/

msm.882607. PMID: 22460104; PMCID: PMC3560813.

[33]Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang

I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the

diagnosis and treatment of pulmonary hypertension: The Joint

Task Force for the Diagnosis and Treatment of Pulmonary

Hypertension of the European Society of Cardiology (ESC)

and the European Respiratory Society (ERS): Endorsed

by: Association for European Paediatric and Congenital

Cardiology (AEPC), International Society for Heart and Lung

Transplantation (ISHLT). Eur Respir J 2015;46:903-975.

[34]Mereles D, Ehlken N, Kreuscher S, Ghofrani S,

Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger

J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens

H, Katus HA, Olschewski H, Grünig E. Exercise and

respiratory training improve exercise capacity and quality of

life in patients with severe chronic pulmonary hypertension.

Circulation. 2006 Oct 3;114(14):1482-9. doi: 10.1161/

CIRCULATIONAHA.106.618397. Epub 2006 Sep 18.

PMID: 16982941.

[35]Grünig E, Ehlken N, Ghofrani A, Staehler G, Meyer

FJ, Juenger J, Opitz CF, Klose H, Wilkens H, Rosenkranz S,

Olschewski H, Halank M. Effect of exercise and respiratory

training on clinical progression and survival in patients

with severe chronic pulmonary hypertension. Respiration.

2011;81(5):394-401. doi: 10.1159/000322475. Epub 2011

Feb 9. PMID: 21311162.

[36]Keusch S, Turk A, Saxer S, Ehlken N, Grunig E,

Ulrich S, On Behalf Of The Swiss Society Of Pulmonary

Hypertension. Rehabilitation in patients with pulmonary

arterial hypertension. Swiss Med Wkly. 2017 Jul 7;147:w14462.

doi: 10.4414/smw.2017.14462. PMID: 28695558.

[37]Rich S, Seidlitz M, Dodin E, Osimani D, Judd D,

Genthner D, McLaughlin V, Francis G. The short-term

effects of digoxin in patients with right ventricular dysfunction

from pulmonary hypertension. Chest. 1998 Sep;114(3):787-

92. doi: 10.1378/chest.114.3.787. PMID: 9743167.

[38]Johnson SR, Mehta S, Granton JT. Anticoagulation

in pulmonary arterial hypertension: a qualitative systematic

review. Eur Respir J. 2006 Nov;28(5):999-1004. doi:

10.1183/09031936.06.00015206. PMID: 17074918.

[39]Prior DL, Adams H, Williams TJ. Update on

pharmacotherapy for pulmonary hypertension. Med J Aust.

2016 Sep 19;205(6):271-6. doi: 10.5694/mja16.00468.

PMID: 27627939.

[40]Lau EMT, Giannoulatou E, Celermajer DS,

Humbert M. Epidemiology and treatment of pulmonary

arterial hypertension. Nat Rev Cardiol. 2017 Oct;14(10):603-

614. doi: 10.1038/nrcardio.2017.84. Epub 2017 Jun 8. PMID:

28593996.

[41]Olsson JK, Zamanian RT, Feinstein JA, Doyle

RL. Surgical and interventional therapies for pulmonary

arterial hypertension. Semin Respir Crit Care Med. 2005

Aug;26(4):417-28. doi: 10.1055/s-2005-916157. PMID:

16121319.

[42]Thenappan T, Ormiston ML, Ryan JJ, Archer SL.

Pulmonary arterial hypertension: pathogenesis and clinical

management. BMJ. 2018 Mar 14;360:j5492. doi: 10.1136/

bmj.j5492. PMID: 29540357; PMCID: PMC6889979.

[43]Zhang H, Wang D, Li M, Plecitá-Hlavatá L,

D'Alessandro A, Tauber J, Riddle S, Kumar S, Flockton

A, McKeon BA, Frid MG, Reisz JA, Caruso P, El Kasmi

KC, Ježek P, Morrell NW, Hu CJ, Stenmark KR.

Metabolic and Proliferative State of Vascular Adventitial

Fibroblasts in Pulmonary Hypertension Is Regulated

Through a MicroRNA-124/PTBP1 (PolypyrimidineTract Binding Protein 1)/Pyruvate Kinase Muscle Axis.

Circulation. 2017 Dec 19;136(25):2468-2485. doi: 10.1161/

CIRCULATIONAHA.117.028069. Epub 2017 Sep 26.

PMID: 28972001; PMCID: PMC5973494.

[44]Caruso P, Dunmore BJ, Schlosser K, Schoors S,

Dos Santos C, Perez-Iratxeta C, Lavoie JR, Zhang H, Long

L, Flockton AR, Frid MG, Upton PD, D'Alessandro A,

Hadinnapola C, Kiskin FN, Taha M, Hurst LA, Ormiston

ML, Hata A, Stenmark KR, Carmeliet P, Stewart DJ, Morrell

NW. Identification of MicroRNA-124 as a Major Regulator

of Enhanced Endothelial Cell Glycolysis in Pulmonary

Arterial Hypertension via PTBP1 (Polypyrimidine Tract

Binding Protein) and Pyruvate Kinase M2. Circulation.

2017 Dec 19;136(25):2451-2467. doi: 10.1161/

CIRCULATIONAHA.117.028034. Epub 2017 Sep 26.

PMID: 28971999; PMCID: PMC5736425.

[45]Pi H, Xia L, Ralph DD, Rayner SG, Shojaie A,

Leary PJ, Gharib SA. Metabolomic Signatures Associated

With Pulmonary Arterial Hypertension Outcomes.

Circ Res. 2023 Feb 3;132(3):254-266. doi: 10.1161/

CIRCRESAHA.122.321923. Epub 2023 Jan 4. PMID:

36597887; PMCID: PMC9904878.

[46]McCaffrey MJ, Bose CL, Reiter PD, Stiles AD.

Effect of L-arginine infusion on infants with persistent

pulmonary hypertension of the newborn. Biol Neonate.

1995;67(4):240-3. doi: 10.1159/000244170. PMID: 7647147.

[ 4 7 ] S h a r i f K a s h a n i B , T a h m a s e b P o u r P ,

Malekmohammad M, Behzadnia N, Sheybani-Afshar F,

Fakhri M, Chaibakhsh S, Naghashzadeh F, Aidenlou S. Oral

l-citrulline malate in patients with idiopathic pulmonary

arterial hypertension and Eisenmenger Syndrome: a clinical

trial. J Cardiol. 2014 Sep;64(3):231-5. doi: 10.1016/

j.jjcc.2014.01.003. Epub 2014 Feb 10. PMID: 24525046.

[48]Bertero T, Oldham WM, Cottrill KA, Pisano S,

Vanderpool RR, Yu Q, Zhao J, Tai Y, Tang Y, Zhang

YY, Rehman S, Sugahara M, Qi Z, Gorcsan J 3rd, Vargas

SO, Saggar R, Saggar R, Wallace WD, Ross DJ, Haley KJ,

Waxman AB, Parikh VN, De Marco T, Hsue PY, Morris

A, Simon MA, Norris KA, Gaggioli C, Loscalzo J, Fessel J,

Chan SY. Vascular stiffness mechanoactivates YAP/TAZdependent glutaminolysis to drive pulmonary hypertension.

J Clin Invest. 2016 Sep 1;126(9):3313-35. doi: 10.1172/

JCI86387. Epub 2016 Aug 22. PMID: 27548520; PMCID:

PMC5004943.


Refbacks

  • 当前没有refback。